Share this Page:
In this phase III study, presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, the use of treatment with pazopanib after surgery to remove renal cell carcinoma (RCC) metastases (metastasectomy) was investigated.
One hundred and twenty-nine patients with no evidence of disease after surgery to remove RCC metastases were randomised to receive pazopanib or placebo for 52 weeks to determine the effects on disease-free survival. Overall survival was significantly better in patients who received placebo compared with those who received pazopanib.
Unfortunately, this study did not show any benefit to receiving treatment with pazopanib for one year following metastasectomy, and there was no improvement in disease-free survival in patients with metastatic RCC who had no evidence of disease after surgery to remove metastases.